RxSight (RXST) Net Income towards Common Stockholders (2020 - 2026)
RxSight filings provide 6 years of Net Income towards Common Stockholders readings, the most recent being -$9.2 million for Q4 2025.
- On a quarterly basis, Net Income towards Common Stockholders fell 142.63% to -$9.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$38.9 million, a 79377.55% decrease, with the full-year FY2025 number at -$38.9 million, down 79377.55% from a year prior.
- Net Income towards Common Stockholders hit -$9.2 million in Q4 2025 for RxSight, up from -$9.8 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $21.5 million in Q4 2024 to a low of -$17.6 million in Q1 2022.
- Median Net Income towards Common Stockholders over the past 5 years was -$10.8 million (2025), compared with a mean of -$9.5 million.
- Biggest five-year swings in Net Income towards Common Stockholders: crashed 5228650.0% in 2022 and later skyrocketed 333.88% in 2024.
- RxSight's Net Income towards Common Stockholders stood at -$15.7 million in 2021, then grew by 0.79% to -$15.6 million in 2022, then skyrocketed by 41.2% to -$9.2 million in 2023, then skyrocketed by 333.88% to $21.5 million in 2024, then plummeted by 142.63% to -$9.2 million in 2025.
- The last three reported values for Net Income towards Common Stockholders were -$9.2 million (Q4 2025), -$9.8 million (Q3 2025), and -$11.8 million (Q2 2025) per Business Quant data.